P797: A PHASE 2, OPEN-LABEL STUDY EVALUATING THE SAFETY AND EFFICACY OF COMBINATION POZELIMAB AND CEMDISIRAN THERAPY IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA WHO SWITCH FROM ECULIZUMAB
Richard Kelly,
Nicola Houghton,
Talha Munir,
Petra Muus,
Nora Youngs,
Lisa Aurand,
Brian Senk,
Rodrigo Pavani,
Lorah Perlee,
Amal Souttou,
Morag Griffin
Affiliations
Richard Kelly
1 St James’s University Hospital, Leeds, United Kingdom
Nicola Houghton
1 St James’s University Hospital, Leeds, United Kingdom
Talha Munir
1 St James’s University Hospital, Leeds, United Kingdom
Petra Muus
1 St James’s University Hospital, Leeds, United Kingdom
Nora Youngs
1 St James’s University Hospital, Leeds, United Kingdom
Lisa Aurand
2 Regeneron Pharmaceuticals, Inc., Tarrytown, United States
Brian Senk
2 Regeneron Pharmaceuticals, Inc., Tarrytown, United States
Rodrigo Pavani
2 Regeneron Pharmaceuticals, Inc., Tarrytown, United States
Lorah Perlee
2 Regeneron Pharmaceuticals, Inc., Tarrytown, United States
Amal Souttou
2 Regeneron Pharmaceuticals, Inc., Tarrytown, United States
Morag Griffin
1 St James’s University Hospital, Leeds, United Kingdom
